Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial

被引：0
|
作者：
Lipton, R. [1 ]
Chalermpalanupap, N. [2 ]
Nahas-Geiger, S. [3 ]
Pozo-Rosich, P. [4 ]
McAllister, P. [5 ]
Tatsuoka, Y. [6 ]
Liu, Y. [7 ]
Dabruzzo, B. [2 ]
Smith, J. [7 ]
Bilchik, T. [8 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] AbbVie, Madison, NJ USA
[3] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] New England Inst Neurol & Headache, Stamford, CT USA
[6] Tatsuoka Neurol Clin, Kyoto, Japan
[7] AbbVie, N Chicago, IL USA
[8] Yale Sch Med, New Haven, CT USA
来源：
HEADACHE | 2023年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-180
引用
收藏
页码：168 / 169
页数：2
相关论文
共 50 条
  • [1] Sustained and Subsequent Response to Atogepant Among Individuals With Episodic Migraine With Prior Treatment Failure: Post Hoc Analysis of the ELEVATE Trial
    Sacco, Simona
    Nagy, Krisztian
    Chalermpalanupap, Natty
    Vernieri, Fabrizio
    Smith, Jonathan H.
    Holle-Lee, Dagny
    Liu, Yingyi
    Carr, Karen
    Pozo-Rosich, Patricia
    Lipton, Richard B.
    CEPHALALGIA, 2023, 43 (1supp) : 265 - 266
  • [2] Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
    Lipton, R. B.
    Chalermpalanupap, N.
    Tatsuoka, Y.
    Nagy, K.
    Liu, Y.
    Carr, K.
    McAllister, P.
    Nahas, S. J.
    Trugman, J. M.
    Sacco, S.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [3] Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
    Dodick, D.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Lipton, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [4] Subsequent response to atogepant in individuals with episodic migraine after an initial inadequate response: Post hoc analyses of a 12-week phase 3 trial
    Dodick, D. W.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Lipton, R. B.
    HEADACHE, 2022, 62 : 164 - 165
  • [5] Post Hoc Analysis of PROGRESS: Evaluating the Safety of Atogepant in Participants With Chronic Migraine and Cardiovascular Risk Factors
    Best, Patricia
    Harriott, Andrea
    Monteith, Teshamae
    Tassorelli, Cristina
    Nahas, Stephanie
    Liu, Yingyi
    Dabruzzo, Brett
    Ferreira, Rosa De Abreu
    Smith, Jonathan H.
    NEUROLOGY, 2023, 100 (17)
  • [6] Post hoc analysis of progress: Evaluating the safety of atogepant in participants with chronic migraine and cardiovascular risk factors
    Best, Patricia
    Harriott, Andrea
    Monteith, Teshamae
    Tassorelli, Cristina
    Nahas, Stephanie
    Davidovic, Goran
    Liu, Yingyi
    Dabruzzo, Brett
    Ferreira, Rosa De Abreu
    Smith, Jonathan
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [7] Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12-and 52-Week Phase 3 Trials
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Dodick, D.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [8] Sustained response to atogepant in individuals with episodic migraine: Post hoc analyses of 12-and 52-week phase 3 trials
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Dodick, D. W.
    HEADACHE, 2022, 62 : 165 - 166
  • [9] Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
    Lipton, Richard B.
    Nahas, Stephanie J.
    Pozo-Rosich, Patricia
    Bilchik, Tanya
    McAllister, Peter
    Finnegan, Michelle
    Liu, Yingyi
    Chalermpalanupap, Natty
    Dabruzzo, Brett
    Dodick, David W.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [10] Atogepant for the preventive treatment of chronic migraine: Results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Goadsby, P. J.
    HEADACHE, 2022, 62 (07): : 923 - 923
12345